×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MGNX – macrogenics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MGNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/26
05:30 pm
mgnx
MacroGenics to Participate in Upcoming Investor Conferences
Neutral
Report
MacroGenics to Participate in Upcoming Investor Conferences
2/24
07:01 am
mgnx
MacroGenics (NASDAQ:MGNX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
MacroGenics (NASDAQ:MGNX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
2/23
06:14 pm
mgnx
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
Low
Report
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
1/9
08:13 am
mgnx
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
Neutral
Report
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
1/3
05:42 am
mgnx
MacroGenics (NASDAQ:MGNX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
MacroGenics (NASDAQ:MGNX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/18
07:02 pm
mgnx
December 2025 Penny Stocks Worth Watching [Yahoo! Finance]
Medium
Report
December 2025 Penny Stocks Worth Watching [Yahoo! Finance]
12/9
04:25 pm
mgnx
MacroGenics (NASDAQ:MGNX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
MacroGenics (NASDAQ:MGNX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/2
04:16 pm
mgnx
Form 8-K MACROGENICS INC For: Mar 02
Low
Report
Form 8-K MACROGENICS INC For: Mar 02
2/24
06:02 am
mgnx
Form 8-K MACROGENICS INC For: Feb 23
High
Report
Form 8-K MACROGENICS INC For: Feb 23
2/17
09:47 pm
mgnx
Form SCHEDULE 13G/A MACROGENICS INC Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SCHEDULE 13G/A MACROGENICS INC Filed by: ARMISTICE CAPITAL, LLC
2/17
06:27 pm
mgnx
Form 4 MACROGENICS INC For: Feb 12 Filed by: Bonvini Ezio
Neutral
Report
Form 4 MACROGENICS INC For: Feb 12 Filed by: Bonvini Ezio
2/17
06:26 pm
mgnx
Form 4 MACROGENICS INC For: Feb 12 Filed by: Smith Beth Ann
Neutral
Report
Form 4 MACROGENICS INC For: Feb 12 Filed by: Smith Beth Ann
2/17
06:26 pm
mgnx
Form 4 MACROGENICS INC For: Feb 12 Filed by: Karrels James
Neutral
Report
Form 4 MACROGENICS INC For: Feb 12 Filed by: Karrels James
2/17
06:25 pm
mgnx
Form 4 MACROGENICS INC For: Feb 12 Filed by: Peters Jeffrey Stuart
Neutral
Report
Form 4 MACROGENICS INC For: Feb 12 Filed by: Peters Jeffrey Stuart
2/17
06:24 pm
mgnx
Form 4 MACROGENICS INC For: Feb 12 Filed by: Spitznagel Thomas
Neutral
Report
Form 4 MACROGENICS INC For: Feb 12 Filed by: Spitznagel Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
Form 4 MACROGENICS INC For: Mar 06 Filed by: Karrels James
10.7%
5/15 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer 10.4%
12/12 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $50.00 price target on the stock. 9.9%
3/23 Form PRE 14A MACROGENICS INC For: May 14 9.8%
4/17 Form 4 MACROGENICS INC For: Apr 16 Filed by: Risser Eric Blasius 8.5%
3/26 MacroGenics Inc (NASDAQ: MGNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 7.9%
11/21 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. 7.9%
2/25 MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.7%
1/13 MacroGenics to Present at the J.P. Morgan Healthcare Conference 7.2%
12/11 MacroGenics down 3% on uncertainty of margetuximab survival benefit [Seeking Alpha] 6.6%
5/15 MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer 10.4%
12/12 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $50.00 price target on the stock. 9.9%
3/23 Form PRE 14A MACROGENICS INC For: May 14 9.8%
4/17 Form 4 MACROGENICS INC For: Apr 16 Filed by: Risser Eric Blasius 8.5%
3/26 MacroGenics Inc (NASDAQ: MGNX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 7.9%
11/21 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. 7.9%
2/25 MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.7%
1/13 MacroGenics to Present at the J.P. Morgan Healthcare Conference 7.2%
12/11 MacroGenics down 3% on uncertainty of margetuximab survival benefit [Seeking Alpha] 6.6%
TOP News Decliners
3/13
Form 4 MACROGENICS INC For: Mar 11 Filed by: Koenig Scott
-20.5%
6/3 MacroGenics: Updating The Investment Thesis [Seeking Alpha] -17.1%
2/27 MacroGenics to Participate in Upcoming Investor Conferences -15.7%
10/22 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer -15.3%
2/28 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.4%
3/7 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -11.9%
3/17 Form 4 MACROGENICS INC For: Mar 13 Filed by: Risser Eric Blasius -9.1%
3/4 MacroGenics Announces Departure of Chief Medical Officer -8.5%
3/25 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.5%
6/5 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -5.9%
6/3 MacroGenics: Updating The Investment Thesis [Seeking Alpha] -17.1%
2/27 MacroGenics to Participate in Upcoming Investor Conferences -15.7%
10/22 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer -15.3%
2/28 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -13.4%
3/7 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -11.9%
3/17 Form 4 MACROGENICS INC For: Mar 13 Filed by: Risser Eric Blasius -9.1%
3/4 MacroGenics Announces Departure of Chief Medical Officer -8.5%
3/25 MacroGenics Inc (NASDAQ: MGNX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.5%
6/5 MacroGenics Inc (NASDAQ: MGNX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: